NCT07320105 2026-01-06Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)Fujian Cancer HospitalPhase 4 Recruiting60 enrolled
NCT05878028 2024-05-23L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLCHenan Cancer HospitalPhase 2 Recruiting33 enrolled